1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Healthcare Information Services
Renalytix Plc

Renalytix Plc

RTNXF
Renalytix PlcUS flagOther OTC
0.08
USD
- -
- -
22.55MMarket Cap
Renalytix Plc
RTNXF
(Other OTC)

Recent

price

0.08

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
TTM
FRC
- -
- -
- -
0.02
0.04
0.04
0.02
0.02
Revenue per Share
- -
-1.13
-0.17
-0.43
-0.62
-0.55
-0.31
-0.23
Basic EPS, GAAP
- -
-0.47
-0.18
-0.37
-0.64
-0.41
-0.28
-0.23
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-1.14
0.59
0.06
-1.82
-2.17
-1.95
-1.5
Book Value per Share
- -
-0.26
0.32
1.08
0.23
0.08
-0.07
-0.01
Tangible Book Value per Share
- -
37
59
71
73
82
108
102
Basic Weighted Avg Shares
- -
- -
- -
1
3
3
2
2
Sales/Revenue/Turnover
- -
- -
- -
-2,187.19
-1,790.67
-1,240.7
-1,261.9
-807.29
Operating Margin (%)
- -
- -
- -
2
- -
1
- -
-1
Depreciation Expense
- -
-42
-10
-31
-45
-46
-33
-23
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
-2,079.81
-1,524.44
-1,340.2
-1,461.6
-987.65
Profit Margin (%)
-1
8
16
69
33
11
-5
7
Working Capital
- -
- -
- -
- -
8
8
4
8
LT Debt
-1
9
36
95
31
7
-8
-1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-158.83
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'24
Sep'25
Dec'25
ST Debt
4
4
- -
LT Borrowings
4
4
8
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
154
166
334
Market Capitalization
15
16
8

Working Capital

FRC

•

in mil. unless spec.
Jun'24
Sep'25
Dec'25
Total Current Assets
6
3
11
Cash, Cash Equivalents & STI
5
1
10
Accounts Receivable, Net
1
1
1
Inventories
- -
- -
- -
Total Current Liabilities
11
12
5
Payables & Accruals
- -
- -
- -
ST Debt
4
4
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
25.44%
-212.73%
Free Cash Flow
- -
28.93%
-11.65%
Net Income, GAAP
- -
31.67%
-26.64%
Sales/Revenue/Turnover
- -
- -
-32.74%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
1
1
1
1
3
2024
- -
1
1
1
2
2025
1
1
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.16
-0.14
-0.14
- -
-0.55
2024
-0.11
- -
-0.08
- -
-0.31
2025
-0.04
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
CE Holdings Co., Ltd. (4320.T)
Certive Solutions Inc. (CTVEF)
Infinitt Healthcare Co Ltd (071200.KS)
Learning 2 Sleep L2S AB (publ) (L2S.ST)
Reliq Health Technologies Inc. (RQHTF)
Cegedim S.A. (CGM.PA)
Business
Renalytix Plc (LSE: RENX; OTCQB: RNLXY) develops artificial intelligence-enabled in vitro diagnostic solutions for kidney disease risk assessment; the company offers KidneyIntelX.dkd, an FDA-approved and Medicare-reimbursed prognostic blood test that combines blood-based biomarkers, genetics, and electronic health record data to stratify patients with type 2 diabetes and early-stage chronic kidney disease (stages 1-3b) into low, moderate, or high risk categories for rapid kidney function decline over five years; it also provides pharmaceutical services leveraging its biomarker portfolio and KidneyIntelX technology for clinical research and drug development support. Incorporated in 2018 and headquartered in New York with a registered office in London, United Kingdom, Renalytix primarily operates in the United States, targeting primary care physicians, nephrologists, and health systems in key markets including New York, Texas, Florida, and Arizona; the company serves approximately 14 million U.S. patients with diabetic kidney disease through electronic medical record integrations that automate patient identification and physician alerts. Recent developments include full Medicare coverage at $950 per test achieved in May 2024, a commercial launch with Advantage Care Physicians serving over 500,000 patients in September 2024, a September 2025 collaboration with Tempus AI to expand national access via precision medicine platforms, and a partnership with MVP Health Care in August 2025 covering 770,000 members in New York and Vermont; the company completed an £11.8 million institutional fundraise in November 2024 and a £6.7 million oversubscribed raise in September 2025, restructured convertible debt to reduce cash obligations by over 80% and extend maturities to 2029, transitioned U.S. trading to OTCQB from Nasdaq in October 2024, appointed Julian Baines as Executive Chairman in 2024 (transitioning to Non-Executive Chairman in January 2026), and reported 30% revenue growth to $3.0 million for fiscal year 2025 with testing volumes up 37%.